Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
Alexandra C HristovTrilokraj TejasviRyan A WilcoxPublished in: American journal of hematology (2023)
PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single-agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.